Myasthenia Gravis Clinical Presentation and Diagnosis

Written by Margaret Anne Rockwood | Last updated March 13, 2026
Medically reviewed by Nizar Souayah, MD

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating, fatigable skeletal muscle weakness due to impaired neuromuscular transmission. Accurate and timely diagnosis is critical, as early intervention improves outcomes and prevents complications such as myasthenic crisis.

Core Symptoms

A patient with MG typically presents with a narrative of fatigable muscle weakness that worsens with repeated use and improves with rest. The path is not linear, as MG symptoms may fluctuate between severe, mild and absent over a period of weeks or months. Clinical remission lasting many years is not uncommon. However, subclinical disease activity may persist, so clinicians should monitor these patients.

In most types of MG (but not in MuSK-positive), the earliest manifestations typically involve ocular musculature, including ptosis and diplopia (double vision). Often, individuals with these symptoms are initially evaluated for everything from vision correction to central nervous system diseases like multiple sclerosis, delaying diagnosis and treatment. Over time, however, weakness may generalize to bulbar, limb, and respiratory muscles, leading to an evaluation by a neurologist.

1. Ocular MG symptoms: Ptosis (often asymmetric and fatigable) and diplopia are early and frequent findings. Between 80-90% of patients experience ocular involvement at some point during their disease. Sometimes, symptoms remain limited to extraocular muscle weakness for prolonged periods, but 50-60% will generalize within 2-3 years.
2. Generalized MG symptoms:

• Bulbar involvement: Dysarthria, dysphagia, nasal speech, and difficulty chewing may predominate early in some patients. Weakness of palatal muscles can result in nasal regurgitation of liquids and aspiration.
• Limb and axial weakness: Proximal muscles are often affected, resulting in difficulty rising from chairs, climbing stairs, or sustaining overhead activity. Extremity weakness can be asymmetrical.
• Respiratory weakness: Though less common at presentation, MG may involve respiratory muscles, contributing to shortness of breath and orthopnea, particularly in advanced disease or myasthenic crisis.

Anti-MuSK positive patients (~5-8% of patients) show prominent facial and bulbar weakness, neck weakness, and more frequent respiratory involvement compared to AChR-positive patients (~75-80% of patients).

Fatigability, the hallmark symptom in MG, typically worsens over the course of the day and with exertion, and improves after periods of rest. Patients may report planning activities early in the day, when strength is better preserved.

Is Myasthenia Gravis Heritable?

MG does not follow Mendelian inheritance, and most patients (95%) do not have any affected family members. However, there is a genetic susceptibility component, in that genes that regulate the immune system can increase risk. Family members may share a risk profile of shared autoimmune vulnerability, but are more likely to develop other autoimmune diseases (thyroid disease, lupus, RA) than MG itself.

Genetic associations with MG include:

1. Certain HLA class II alleles (especially HLA-DR and HLA-DQ variants)
2. Variants involved in T-cell activation and immune regulation

The heritability factor is so rarely consequential that routine genetic testing is not indicated and family members do not need screening unless symptomatic.

Diagnosis

Clinical Evaluation

Diagnosis begins with a detailed history and neurological examination focusing on fatigable weakness in characteristic muscle groups. Differentiation of true neuromuscular weakness from nonspecific fatigue or somnolence is essential; weakness that increases with repetitive activity and diminishes with rest is suggestive of MG.

Standard neurological assessment includes evaluation of:

1. Cranial nerve function
2. Muscle strength and fatigability
3. Reflexes and coordination

Specific bedside maneuvers, such as prolonged upward gaze to provoke ptosis or sustained arm elevation to induce weakness, may help begin the differential diagnosis.

Serologic Testing

Blood tests for autoantibodies are central to confirming MG:

1. AChR antibodies: Present in approximately 80–85% of generalized MG patients and ~50% in ocular-only MG.
2. MuSK antibodies: Detected in 5-8% of patients, particularly when AChR tests are negative.
3. LRP4 and agrin antibodies: Rare, but may be pursued if both AChR and MuSK tests are negative.

Seronegative MG remains a diagnostic challenge; absence of detectable antibodies does not rule out MG clinically, when clinical and electrophysiological features show evidence.

Electrophysiological Testing

When the history and exams are suggestive of MG, but serology is inconclusive, electrophysiological studies help confirm impaired neuromuscular transmission.

These include:

1. Repetitive Nerve Stimulation (RNS): A decremental response on slow-frequency stimulation supports MG diagnosis, particularly in generalized MG.
2. Single-Fiber Electromyography (SFEMG): The most sensitive test, detecting abnormal neuromuscular jitter and blocking.

Historically, the edrophonium (Tensilon) test was used to support diagnosis, but it is less common in modern practice due to low availability and risk considerations.

Imaging

Structural imaging of the anterior mediastinum via CT or MRI is recommended to evaluate for thymic abnormalities, including thymoma or hyperplasia, which are present in a significant subset of MG patients, and influence management decisions.

Diagnostic Pitfalls and Considerations

1. MG symptoms frequently fluctuate and may be mild early on, leading to diagnostic delay.
2. A negative antibody panel does not exclude MG. Standard radioimmunoassays (RIA) may fail to detect low-affinity or low-titer antibodies, particularly in early or ocular MG.

Notes: If clinical suspicion remains high, repeat antibody testing or use more sensitive methods, such as cell-based assays (CBA), to detect antibodies against clustered acetylcholine receptors that are missed by conventional assays.

Retesting may also be warranted when symptoms progress or generalize, as some patients initially classified as seronegative later test positive for AChR, MuSK, or LRP4 antibodies with more sensitive testing.

Mimics to Watch For

1. Other conditions like cranial nerve palsies, motor neuron diseases and central nervous system disorders like multiple sclerosis can mimic MG. To distinguish MG from these mimics, look for the combination of preserved reflexes, fluctuating weakness and fatigability.
2. Congenital Myasthenic Syndromes (CMS) are an ultra-rare mimic of true MG. These are heritable, but clinically and mechanistically, they are a completely different category of disease. The term “myasthenic” refers to shared clinical features (fatigable weakness), not shared pathogenesis. A CMS results from inherited mutations in proteins essential to the neuromuscular junction, leading to impaired synaptic transmission.

• A CMS presents from birth or early childhood, though mild forms may appear later. Features include hypotonia, delayed motor milestones, ptosis, and fatigable weakness.
• Distinguish CMS from MG by the absence of autoantibodies, the lack of response to or possible worsening of symptoms with immunotherapy, and genetic testing confirming pathogenic variants associated with CMS.

In summary, early recognition of myasthenia gravis hinges on scrutinizing the pattern of muscle weakness and confirming through antibody and electrophysiology testing. Imaging is integral to evaluate thymic pathology.

Treatment begins from there, and with attentive management, it can offer life-altering consequences for quality living and a normal or near-normal life span.

References

1. Myasthenia gravis: diagnosis. Meriggioli, M. N., & Sanders, D. B. (2004). Seminars in Neurology, 24(1), 31–39.
2. Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations. Dresser, L., Wlodarski, R., Rezania, K., & Soliven, B. (2021). Journal of Clinical Medicine, 10(11), 2235.
3. Diagnosis of myasthenia gravis. Pasnoor, M., Dimachkie, M. M., Farmakidis, C., & Barohn, R. J. (2018). Neurologic Clinics, 36(2), 261–274.
4. Generalized myasthenia gravis: Classification, clinical features, and natural history. Hehir, M. K., & Silvestri, N. J. (2018). Neurologic Clinics, 36(2), 253–260.
5. Myasthenia gravis. Gilhus, N. E., et al. (2019). Nature Reviews Disease Primers, 5, 30.
6. International consensus guidance for management of myasthenia gravis. Sanders, D. B., Wolfe, G. I., Benatar, M., et al. (2016). Neurology, 87(4), 419–425.
7. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Evoli, A., & Padua, L. (2013). Autoimmunity Reviews, 12(9), 931–935.
8. Clinical value of cell-based assays in the diagnosis of myasthenia gravis. Damato, V., et al. (2022). Frontiers in Neurology, 13, 89570.
9. The clinical need for clustered AChR cell-based assay testing of seronegative myasthenia gravis. Masi, G., et al. 2022; Journal of Neuroimmunology, 367:577850.
10. Bedside and laboratory diagnostic testing in myasthenia gravis. Yoganathan, K., et al. (2022). Journal of Neurology.
11. Electrophysiologic evaluation of myasthenia gravis and its mimics. Khoo, A., et al. (2022). Expert Review of Neurotherapeutics.
12. Electrodiagnostic criteria for neuromuscular transmission disorders. Tankisi, H., et al. (2025). Clinical Neurophysiology Practice.
13. Ocular myasthenia gravis: current diagnostic and treatment approaches. Kupersmith, M. J., et al. (2025). Frontiers in Neurology.